Johnson & Johnson (JNJ) , via its subsidiary called Red River Talc, for the third time, filed for voluntary bankruptcy to resolve thousands of lawsuits related to its talc products. Red River Talc has filed for Chapter 11 bankruptcy to equitably resolve all of JNJ’s present and future talc-related claims in a bankruptcy court in the Southern District of Texas.JNJ faces more than 62,000 lawsuits for its talc-based products, primarily its baby powders. The lawsuits allege that its talc products contain asbest ...

If you liked this idea, sign up for a no-obligation free trial of my Seeking Alpha Marketplace service, Timely Trader ! I sift through various asset classes to find the best places for your capital, helping you maximize your returns. Timely Trader seeks to find winners before they become winners, and keep you out of losers. In addition, you get access to our community via chat, direct access to me, real-time price alerts, a model portfolio, and more.The bout of selling we've seen in the equity markets since ...

文章核心观点 - 强生公司(JNJ)宣布FDA批准其EGFR/MET抑制剂Rybrevant(amivantamab)与标准化疗(卡铂和培美曲塞)的联合疗法,用于治疗某些非小细胞肺癌(NSCLC)患者 [1][2] - 这一批准是基于III期MARIPOSA-2研究的数据,该研究评估了Rybrevant-化疗联合疗法在EGFR 19外显子缺失或L858R替换NSCLC患者中的疗效和安全性 [2] - 该研究达到了主要终点,Rybrevant-化疗联合疗法相比单独化疗可将疾病进展或死亡风险降低52% [2] - 强生公司正在评估Rybrevant在其他适应症如转移性结直肠癌中的应用 [6] 根据目录分类总结 公司动态 - 这是Rybrevant今年获得的第三项FDA批准 [4] - 强生公司还提交了Rybrevant皮下给药剂型的监管申请,并获得优先审评 [5] - 强生公司目前的股票评级为卖出评级 [7] 行业动态 - Rybrevant旨在与阿斯利康的Tagrisso竞争,后者是EGFR突变NSCLC的当前标准治疗 [5] - 强生公司的同行中,Illumina和Krystal Biotech的股票评级为强烈买入 [7][8]

文章核心观点 - 公司在新加坡已经运营50年,一直致力于通过创新的药品和医疗技术解决方案来改善新加坡人的生活 [1] - 公司邀请患者及其家人分享他们的故事,记录公司创新药品和医疗技术解决方案对他们生活的重大影响 [2] - 公司员工参与的全球性自行车活动成功为全球1000多例有意义的手术筹集了资金,通过支持微笑行动为有需要的儿童带来笑容 [1][5] 公司在新加坡的发展历程 - 公司在新加坡设立了东南亚机器人辅助手术体验中心,让外科医生能够通过干练和手术模拟探索全膝关节置换手术 [3] - 公司在新加坡推出了首个针对复发/难治性多发性骨髓瘤患者的B细胞成熟抗原(BCMA)定向CD3 T细胞重定向双特异性抗体 [4] - 公司是新加坡眼健康创新产品的首选市场,包括从隐形眼镜到屈光和白内障手术解决方案 [4] - 公司与新加坡经济发展局合作,利用JLABS的服务和创新资源,加速早期发现转化为创新药物、医疗技术和数字健康技术解决方案 [4] 公司的社会责任 - 公司员工参与了一项名为"为儿童骑行"的健康公平活动,为微笑行动筹集资金,为唇腭裂患者提供医疗救助 [5][6] - 公司鼓励公众在2024年9月19日至10月18日期间,通过电子邮件向公司分享他们的故事 [6]

文章核心观点 - 从估值角度来看,迪士尼(DIS)股票目前比强生(JNJ)更具吸引力 [1][10] - 强生股价在过去3年中表现优于迪士尼,但两者的收益波动都不如标普500指数 [2][3] - 迪士尼的收入增长率高于强生,但强生的盈利能力更强 [4][5][6][8] - 强生的财务风险较低,资产负债表更加稳健 [9] 根据相关目录分别进行总结 收入增长 - 强生2021-2023年调整后收入增长8%,从787亿美元增至852亿美元 [4] - 强生收入增长主要来自制药和医疗器械业务,其中多发性骨髓瘤药物Darzalex和自身免疫药物Stelara表现强劲 [5] - 迪士尼2021-2023财年收入增长32%,从674亿美元增至889亿美元,主要得益于主题公园业务的反弹和流媒体业务的增长 [6] 盈利能力 - 强生的营业利润率从2021年的26.6%扩大至2023年的27.5% [8] - 迪士尼的营业利润率从2021年的5.4%上升至2023年的10.1%,但仍低于强生 [8] 财务风险 - 强生的债务占权益比仅10%,远低于迪士尼的29% [9] - 强生的现金占资产比例为14%,高于迪士尼的3% [9]

Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.13%. On the other hand, the Dow registered a gain of 0.55%, and the technology-centric Nasdaq decreased by 0.52%.Coming into today, shares of the world's biggest maker of health care products had gained 3.85% in the past month. In that same time, the Medical sector gained 3.34%, while the S&P 500 gained 3.67%.Market partici ...

TAR-200 plus cetrelimab effective in reducing tumor size in those with muscle-invasive disease, potentially improving surgical outcomes and lowering risk of recurrenceBARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today interim data from the ongoing Phase 2 SunRISe-4 study showing neoadjuvant treatment with investigational TAR-200 plus cetrelimab (CET) achieved nearly double the pathological complete response (pCR) rate compared to CET alone in patients with muscle- ...

Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of diseaseNew results show potential of RYBREVANT® beyond lung cancer BARCELONA, Sept. 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) ...

文章核心观点 - RYBREVANT®(amivantamab-vmjw)与化疗联合治疗在既往接受过奥希替尼治疗的非小细胞肺癌患者中,在疾病进展后的预后结果方面显示出显著且持续的改善[1] - 与单用化疗相比,RYBREVANT®联合化疗组在总生存期方面呈现有利趋势[1] - RYBREVANT®联合化疗组患者在治疗中断率、症状进展时间和后续治疗时间等方面均显著优于单用化疗组[1] 根据目录分类总结 疗效相关 - RYBREVANT®联合化疗组在18个月时的生存率为50%,高于单用化疗组的40%,中位总生存期分别为17.7个月和15.3个月[1] - RYBREVANT®联合化疗组患者在治疗中断率、症状进展时间和后续治疗时间等方面均显著优于单用化疗组[1] - RYBREVANT®联合化疗组患者的疾病进展后第二次进展或死亡风险降低36%[1] 安全性相关 - RYBREVANT®联合化疗的安全性与单药及联合用药的既定安全性一致[1][2] - 11%的患者因不良反应永久性停用RYBREVANT®[1] 临床试验相关 - MARIPOSA-2是一项随机、开放标签的III期临床试验,评估RYBREVANT®(单药或联合LAZCLUZE™)与化疗的疗效和安全性[2][3] - 该试验共入组657例既往接受过奥希替尼治疗的局部晚期或转移性EGFR外显子19缺失或L858R突变非小细胞肺癌患者[3] [1] [2] [3]

Johnson & Johnson (JNJ) announced that the FDA approved its blockbuster immunology medicine, Tremfya (guselkumab), for a third indication. The drug is approved to treat adults with moderately to severely active ulcerative colitis (UC).Tremfya is already approved for plaque psoriasis and active psoriatic arthritis (PsA) indications in several countries, including the United States and Europe.This latest approval is based on data from the phase IIb/III QUASAR study, which showed that a significantly greater p ...